Skip to main content

Advertisement

SpringerLink
Log in

SEOM clinical guidelines for the treatment of head and neck cancer

  • Clinical Guides in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Head and neck cancer constitutes the fifth highest cause of cancer in Spain. It is a neoplasm with a high possibility of cure if it is diagnosed in early stages, but unfortunately two thirds of the patients are diagnosed at an advanced loco-regional stage (stage III and IV, without metastasis). The multidisciplinary team, bringing together all professionals who specialize in the diagnosis and treatment of these tumors make the decision to establish the best sequence of individualized diagnosis, staging and treatment for each patient. This guide gives recommendations for diagnosis, staging and treatment for squamous cell carcinoma of the head and neck. In order to simplify the amount of information about any subsite of the head and neck area, the treatment recommendations are summarized as local disease, locally advance resectable and unresectable stages, function-preserving laryngeal treatment and recurrent and metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Borras J, Borras JM, Galcerán J et al (2001) Tendencia del cáncer relacionado con el tabaco en Tarragona, España, 1980–96. Cancer Causes Control 12:903–908

    Article  CAS  PubMed  Google Scholar 

  2. Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. IARC Press, Lyon

    Google Scholar 

  3. TNM Classification (2002) In: AJCC Cancer Staging Manual, 6th edn. Springer, New York, NY

    Google Scholar 

  4. Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer. N Engl J Med 345: 1890–1900

    Article  CAS  PubMed  Google Scholar 

  5. Winquist E, Oliver T, Gilvert R (2007) Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. Head Neck 29:38–46

    Article  PubMed  Google Scholar 

  6. Pignon JP, Bourhis J, Domenge C, Designé L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355:949–955

    CAS  PubMed  Google Scholar 

  7. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  CAS  PubMed  Google Scholar 

  8. Bonner JA, Harari PM, Giralt J et al (2009) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

    Article  PubMed  Google Scholar 

  9. Vermorken JB, Remenar E, Van Herpen C et al (2007) Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. Phase III trial EORTC 24971/TAX 323. N Engl J Med 357:1695–1704

    Article  CAS  PubMed  Google Scholar 

  10. Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. TAX 324 Study Group. N Engl J Med 357:1705–1725

    Google Scholar 

  11. Lefebvre JL, And KK (2009) Larynx preservation clinical trial design: key issues and recommendations. A consensus panel summary. Int J Radiat Oncol Biol Phys 73:1293–1303

    PubMed  Google Scholar 

  12. (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685–1690

  13. Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098

    Article  CAS  PubMed  Google Scholar 

  14. Forastiere AA, Maor M, Weber RS et al (2006) Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx. Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 24[18S]:5517

    Google Scholar 

  15. Pointreau Y, Garuad P, Chapet S et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498–506

    Article  CAS  PubMed  Google Scholar 

  16. Bonner JA, Harare M, Giralt J et al (2005) Improved preservation of larynx with the addition of cetuximab to radiotherapy for cancers of the larynx and hypopharynx. J Clin Oncol 23[16S]: 5533

    Google Scholar 

  17. Hitt R, López-Pousa A, Martínez-Trufero J et al (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636–8645

    Article  PubMed  Google Scholar 

  18. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127

    Article  CAS  PubMed  Google Scholar 

  19. Hitt R, Irigoyen A, Nuñez J et al (2007) Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC). J Clin Oncol 25[18S]:6012

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Institut Català d’Oncologia, L’Hospitalet de Llobregat, Avda. Gran Vía, s/n, km. 2,700, ES-08907, Barcelona, Spain

    Ricard Mesía Nin

  2. Servicio de Oncología Médica, Hospital General Universitario La Fe, Valencia, Spain

    Miguel Pastor Borgoñón

  3. Servicio de Oncología Médica, Hospital Universitario, Salamanca, Spain

    Juan Jesús Cruz Hernández

  4. Servicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

    Dolores Isla Casado

Authors
  1. Ricard Mesía Nin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miguel Pastor Borgoñón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Jesús Cruz Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dolores Isla Casado
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ricard Mesía Nin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mesía Nin, R., Pastor Borgoñón, M., Cruz Hernández, J.J. et al. SEOM clinical guidelines for the treatment of head and neck cancer. Clin Transl Oncol 12, 742–748 (2010). https://doi.org/10.1007/s12094-010-0589-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-010-0589-2

Keywords

Search

Navigation